Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH”by Both Completer and ITT Analyses”at Week 96 in Phase 2

6 months ago 36

1. Homepage
2. Finance
3. Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH”by Both Completer and ITT Analyses”at Week 96 in Phase 2